Ocumension Therapeutics cancels options, issues new grants and awards

On June 24, 2025, Ocumension Therapeutics announced the cancellation of 4,018,842 existing options and the re-grant of 2,813,189 replacement options to 155 existing grantees, representing approximately 0.35% of the company's total issued shares. The exercise price of the replacement options is set at HKD 10.98 per share. In addition, the Board has approved the grant of 15,462,865 new options and 8,952,185 award shares to 430 grantees, representing 1.90% and 1.10% of the total shares in issue, respectively. CEO Ye Liu will receive 7,324,515 options, while Dr. Hu will receive 100,000 options and 27,000 awards. The new options vest over time with performance-based conditions for Mr. Liu and discretionary performance targets for other grantees. The company believes these measures will incentivize talent, support growth, and enhance shareholder value.